Advances in Malignant Mesothelioma

Robinson, Bruce W.S.; Lake, Richard A.

doi:10.1056/nejmra050152

Cited by 889

The DOI matches its Crossref record.

Advances in Malignant Mesothelioma

Robinson, Bruce W.S., Lake, Richard A.·2005·New England Journal of Medicine

DOI 10.1056/nejmra050152

Open this paper in CoChat — free account

Abstract

Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura and the peritoneum. This tumor was once rare, but its incidence is increasing worldwide, probably as a result of widespread exposure to asbestos, a factor with which it is associated. The authors review advances made in the past 5 to 10 years in the understanding, diagnosis, and management of mesothelioma.

Integrity signals

Registry

Crossref · 10.1056/nejmra050152

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

No references could be resolved yet.

Research works printed but not linked: 85

10.1016/S0140-6736(00)04013-7 · DOI
10.1093/carcin/15.11.2673 · DOI
Sebastien P, 1980, IARC Sci Publ, 30, 237
Wagner JC, 1960, Br J Ind Med, 17, 260
10.1097/00063198-200007000-00003 · DOI
10.1016/S1055-3207(03)00045-0 · DOI
10.1016/j.lungcan.2004.04.006 · DOI
10.1111/j.1445-5994.1991.tb01355.x · DOI
10.1097/00063198-199907000-00015 · DOI
10.1007/BF01519898 · DOI · Paper page
Hodgson JT, 2000, Ann Occup Hyg, 44, 565, 10.1093/annhyg/44.8.565 · DOI
10.1080/01913120252959227 · DOI · Paper page
10.1002/1097-0142(19930715)72:2<389::AID-CNCR2820720213>3.0.CO;2-V · DOI · Paper page
Carbone M, 1994, Oncogene, 9, 1781
10.1016/S0140-6736(02)07921-7 · DOI
MacLachlan DS, 2002, Anticancer Res, 22, 3495
10.2307/3580117 · DOI
10.1016/S0140-6736(83)90104-6 · DOI
10.1038/sj.bjc.6690105 · DOI
Ault JG, 1995, Cancer Res, 55, 792
Kamp DW, 1995, Am J Physiol, 268, 471
Zanella CL, 1996, Cancer Res, 56, 5334
Balsara BR, 1999, Cancer Res, 59, 450
10.1038/bjc.1997.91 · DOI
10.1002/ijc.2910520609 · DOI
Cicala C, 1993, Am J Pathol, 142, 1524
10.1016/S0092-8674(00)81683-9 · DOI · Paper page
Versnel MA, 1991, Oncogene, 6, 2005
Garlepp MJ, 1993, Eur Respir Rev, 3, 192
10.1038/bjc.1990.207 · DOI
10.3109/08977199409015049 · DOI
Marzo AL, 1997, Cancer Res, 57, 3200
10.1038/sj.onc.1207881 · DOI
10.1002/(SICI)1096-9896(200001)190:1<80::AID-PATH498>3.0.CO;2-7 · DOI
10.1016/S0169-5002(02)00178-2 · DOI
10.1093/jnci/92.8.636 · DOI
Schipper H, 2003, Int J Oncol, 22, 1009
10.1038/nrm1496 · DOI
10.1074/jbc.M408190200 · DOI
10.1002/ijc.10996 · DOI
10.1016/j.athoracsur.2004.03.021 · DOI
10.1378/chest.124.5.1916 · DOI
10.1016/S1357-2725(03)00242-5 · DOI
10.1038/sj.bjc.6600920 · DOI
10.1111/j.1600-0609.1994.tb01277.x · DOI
Robinson C, 2000, Am J Respir Cell Mol Biol, 22, 550, 10.1165/ajrcmb.22.5.3930 · DOI
10.1054/bjoc.2000.1529 · DOI
10.1046/j.1365-2303.2000.00247.x · DOI
10.1002/(SICI)1097-0142(19980201)82:3<583::AID-CNCR22>3.0.CO;2-X · DOI
Whitaker D, 1992, Semin Diagn Pathol, 9, 151
10.1111/j.1440-1843.2004.00599.x · DOI
10.1148/rg.241035058 · DOI
10.1016/S0022-5223(03)00207-1 · DOI
Goerres GW, 2004, J Nucl Med, 45, 66S
10.1016/S0140-6736(03)14794-0 · DOI
10.1093/annonc/mdi004 · DOI
Byrne MJ, 1999, J Clin Oncol, 17, 25, 10.1200/JCO.1999.17.1.25 · DOI
10.1081/CNV-120030219 · DOI
Singhal S, 2003, Clin Cancer Res, 9, 3080
Gordon GJ, 2002, Cancer Res, 62, 4963
10.1016/j.lungcan.2004.04.025 · DOI
10.1378/chest.113.3.723 · DOI
10.1016/0169-5002(95)00508-0 · DOI
Rusch VW, 1999, Chest Surg Clin N Am, 9, 327
10.1016/j.lungcan.2004.04.018 · DOI
10.1016/j.jtcvs.2004.02.021 · DOI
10.1016/j.athoracsur.2004.01.034 · DOI
10.1007/BF02306613 · DOI
10.3816/CLC.2003.n.023 · DOI
10.1200/JCO.2003.11.136 · DOI · Paper page
10.1038/sj.bjc.6600505 · DOI
10.1053/sonc.2002.30234 · DOI
10.1016/S1547-4127(04)00108-2 · DOI
10.1097/00130404-200311000-00008 · DOI
10.1378/chest.112.4_Supplement.276S · DOI
Webster I, 1982, S Afr Med J, 61, 277
10.1016/S0169-5002(00)00192-6 · DOI
Robinson BWS, 1991, Interferons Cytokines, 18, 5
10.1097/00002371-199809000-00007 · DOI
10.1038/sj.cgt.7700133 · DOI
10.1016/S0889-8588(05)70008-3 · DOI
10.1378/chest.120.4.1167 · DOI
10.1016/j.lungcan.2004.04.022 · DOI
10.1158/1078-0432.CCR-03-0801 · DOI
Nowak AK, 2003, Cancer Res, 63, 4490

Sorted by citations

Deep learning-based classification of mesothelioma improves prediction of patient outcome
Courtiol, P., Maussion, C., Moarii, M., Pronier, E., Pilcer, S., Sefta, M., Manceron, P., Toldo, S., Zaslavskiy, M., Le Stang, N., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0583-3 · Cited by 544
Malignant Mesothelioma: Global Incidence and Relationship with Asbestos
BIANCHI, C., & BIANCHI, T. (2007) · Industrial Health · doi:10.2486/indhealth.45.379 · Cited by 261
Asbestos-induced lung diseases: an update
Kamp, D. W. (2009) · Translational Research · doi:10.1016/j.trsl.2009.01.004 · Cited by 251
TGF-β Synergizes with Defects in the Hippo Pathway to Stimulate Human Malignant Mesothelioma Growth
Fujii, M., Toyoda, T., Nakanishi, H., Yatabe, Y., Sato, A., Matsudaira, Y., Ito, H., Murakami, H., Kondo, Y., Kondo, E., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111653 · Cited by 224
Foxp3 expressing CD4+ CD25+ and CD8+CD28− T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma
Meloni, F., Morosini, M., Solari, N., Passadore, I., Nascimbene, C., Novo, M., Ferrari, M., Cosentino, M., Marino, F., Pozzi, E., et al. (2006) · Human Immunology · doi:10.1016/j.humimm.2005.11.005 · Cited by 169

See all 889

Authors: Robinson, B. W. S., & Lake, R. A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-10-13
Volume: 353
Issue: 15
Pages: 1591-1603
ISSN: 0028-4793
1533-4406
DOI: 10.1056/nejmra050152
Cited by: 889
References: 0
Language: en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page: CoChat. (2026). Citation check: Advances in Malignant Mesothelioma. https://app.cochat.ai/papers/10.1056/nejmra050152
The paper: Robinson, B. W. S., & Lake, R. A. (2005). Advances in Malignant Mesothelioma. New England Journal of Medicine. https://doi.org/10.1056/nejmra050152

Advances in Malignant Mesothelioma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Metadata

Record

About these checks

How to cite